ROS1 gene rearrangements, although not routinely screened, are present in 1–2% of non-squamous NSCLC patients, and their significant intracranial response rates with TKIs should prompt regular ROS1 testing, particularly in brain metastases patients [80]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.